Compare TLYS & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLYS | LITS |
|---|---|---|
| Founded | 1982 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.2M | 54.1M |
| IPO Year | 2012 | N/A |
| Metric | TLYS | LITS |
|---|---|---|
| Price | $1.69 | $1.42 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.25 | N/A |
| AVG Volume (30 Days) | 83.1K | ★ 781.2K |
| Earning Date | 12-03-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $545,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $1.30 |
| 52 Week High | $4.60 | $9.00 |
| Indicator | TLYS | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | N/A |
| Support Level | $1.58 | N/A |
| Resistance Level | $1.86 | N/A |
| Average True Range (ATR) | 0.14 | 0.00 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 22.66 | 0.00 |
Tilly's Inc works as a specialty retailer of casual apparel, footwear, and accessories for young men, young women, boys, and girls. It offers an unparalleled selection of relevant brands, styles, colors, sizes, and price points. It delivers branded fashion, and core styles for tops, outerwear, bottoms, and dresses. It also provides backpacks, hats, sunglasses, headphones, handbags, watches, and jewelry. It markets its products under the brand names of Vans, RVCA, Adidas, Nike SB, and Hurley among others. It operates its stores in malls, lifestyle centers, power centers, community centers, outlet centers, street-front locations, and also through e-commerce.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.